Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy

Journal of Pediatric Infectious Diseases

Volumn 34, Issue 2, 2015, Pages e23-e31

  Bwakura Dangarembizi, Mutsawashe ^a   Musiime, Victor ^b,c   Szubert, Alexander J ^d   Prendergast, Andrew J ^d,e   Gomo, Zvenyika A ^a   Thomason, Margaret J ^d   Musarurwa, Cuthbert ^a   Mugyenyi, Peter ^b   Nahirya, Patricia ^f   Kekitiinwa, Adeodata ^g   Gibb, Diana M ^d   Walker, Ann S ^d   Nathoo, Kusum ^a  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c MAKERERE UNIVERSITY   (Uganda)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^g MULAGO HOSPITAL   (Uganda)

Author keywords

Africa; Antiretroviral therapy; Children; HIV; Lipids; Lipodystrophy

Indexed keywords

ABACAVIR; ALBUMIN; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; ANTIRETROVIRUS AGENT; LIPID; DIDANOSINE; HIGH DENSITY LIPOPROTEIN;

AFRICAN; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARM CIRCUMFERENCE; ARTICLE; BODY BUILD; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HIP CIRCUMFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; OPEN STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SKINFOLD THICKNESS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UGANDA; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ZIMBABWE; ADOLESCENT; ADVERSE EFFECTS; BLOOD; BODY FAT DISTRIBUTION; CHEMICALLY INDUCED; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INFANT; PRESCHOOL CHILD; PROCEDURES; ANTIRETROVIRAL THERAPY; BODY SIZE; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; THIGH CIRCUMFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY FAT DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LIPIDS; LIPODYSTROPHY; MALE; PREVALENCE; UGANDA; ZIMBABWE;

EID: 84925640301     PISSN: 13057707     EISSN: 13057693     Source Type: Journal    
DOI: 10.1097/INF.0000000000000491     Document Type: Article

References (51)

1. Alam N, Cortina-Borja M, Goetghebuer T, et al; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr. 2012;59:314-324.
2. Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-410.
3. Arpadi SM, Bethel J, Horlick M, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS. 2009;23:1501-1509.
4. Aurpibul L, Puthanakit T, Lee B, et al. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther. 2007;12:1247-1254.
5. Badillo K, Prieto L, Toledano M, et al. Characteristics of human immunodeficiency virus-1 infected children receiving highly active antiretroviral therapy: a cross-sectional study. An Pediatr (Barc) 2012;76:317-323.
6. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:161-168.
7. Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr. 2007;166:13-21.
8. European Paediatric Lipodystrophy G. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004,18:1443-1451.
9. Innes S, Cotton MF, Haubrich R, et al. High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr. 2012;12:183.
10. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123-2128.
11. Jevtović D, Salemović D, Ranin J, et al. The prognosis of pediatric AIDS in serbia. Curr HIV Res. 2009;7:287-292.
12. Kanjanavanit S, Puthanakit T, Vibol U, et al; PREDICT study group. High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression. Antivir Ther. 2011;16:1351-1355.
13. Kinabo GD, Sprengers M, Msuya LJ, et al. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J. 2013;32:39-44.
14. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, et al. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc. 2012;15:17427.
15. Alves C, Oliveira AC, Brites C. Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. Braz J Infect Dis. 2008;12:342-348.
16. Arpadi SM, Cuff PA, Horlick M, et al. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27:30-34.
17. Carter RJ, Wiener J, Abrams EJ, et al; Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr. 2006;41:453-460.
18. Resino S, Palladino C, Lorente R, et al Spanish Group of Pediatric HIV Infection. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy. Pediatr Infect Dis J. 2010;29:774-777.
19. UNAIDS. Global report: UNAIDS Report on the Global AIDS Epidemic 2012. Geneva, Switzerland: UNAIDS, 2012.
20. Arpadi S, Shiau S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013;98:258-264.
21. Musiime V, Cook A, Kayiwa J, et al. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3-trial. Antivir Ther. 2014;19:269-276.
22. Ministry of Health - Kenya. Guidelines for Antiretroviral Therapy in Kenya. 4th ed. Available at: http://www.aidstar-one.com/sites/default/files/treatment/national-treatment-guidelines/Kenya-2011-tagged.pdf. 2011. Accessed March 15, 2014.
23. Ministry of Health-Uganda. Addendum to the Antiretroviral Treatment Guidelines Available at: http://www.kisiizihospital.org.ug/wp-content/uploadedfiles/2013/10/Addednum-National-ART-Rx-Guidelines-Dec-2013.pdf. 2013. Accessed March 15, 2014.
24. RESAPSI/CNLS. Workshop Summary. Workshop on Strategies for Antiretroviral Therapy and Prevention of HIV Infection in Sub Saharan Africa (Saly, Senegal, 6-8 February 2014).
25. Lucey JM, Hsu P, Ziegler JB. Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV. BMJ Case Rep. [published online July 9, 2013]. doi: 10.1136/bcr-2013-008674.
26. Purswani M, Patel K, Kopp JB, et al Pediatric HIVAIDS Cohort Study. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495-500.
27. Medecins San Frontieres. Untangling the Web of Antiretroviral Price Reductions. 16th ed. Available at: http://d2pd3b5abq75bb.cloudfront.net/2013/09/11/10/25/44/896/MSF-Access-UTW-16th-Edition-2013.pdf. 2013. Accessed March 15, 2014.
28. de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013;8:e63623.
29. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403-1412.
30. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012;59:274-280.
31. Arrow Trial Team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013;381:1391-1403.
32. World Health Organisation. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach. Available at: http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf. Accessed May 3, 2013.
33. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books; 1988.
34. Fredriks AM, van Buuren S, Fekkes M, et al. Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice? Eur J Pediatr. 2005;164:216-222.
35. Gerver WJM, de Bruin R. Paediatric Morphometrics: A Reference Manual. Maastricht, The Netherlands: Universitaire Pers Maastricht; 2001.
36. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med. 1994;13:2359-2367.
37. National Institute for Allergy and Infectious Disease (NIAID). Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. Available at: http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidsaegradingtable.pdf. Accessed March 10, 2014.
38. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert Panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011,128:S213-S256.
39. Aurpibul L, Puthanakit T, Taejaroenkul S, et al. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2012;31:384-388.
40. Green H, Gibb DM, Walker AS, et al Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947-955.
41. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359:733-740.
42. Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, et al. Virologic response in children treated with abacavir compared with stavudine-based antiretroviral treatment - a South African multi-cohort analysis. Pediatr Infect Dis J. 2014;33:617-622.
43. Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev 2010:CD008651.
44. Liu E, Armstrong C, Spiegelman D, et al. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. Clin Infect Dis. 2013;56:1820-1828.
45. da Luz PL, Favarato D, Faria-Neto JR Jr, et al. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo). 2008;63:427-432.
46. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
47. Parienti JJ, Massari V, Rey D, et al; SIROCCO study team. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45:263-266.
48. Federal Drug Authority. Sustiva (efavirenz) pediatric patients labeling update Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm350744.htm. Accessed November 4, 2013.
49. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA. 2013;309:1803-1809.
50. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed March 10, 2014.
51. Rhoads MP, Lanigan J, Smith CJ, et al. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr. 2011;57:404-412.